Mark A. Rubin , M.D.
Director, Caryl and Israel Englander Institute for Precision Medicine
Homer T. Hirst Professor of Oncology in Pathology
Vice Chair for Molecular and Genomic Pathology
Dr. Rubin is a recognized world leader in the area of prostate cancer genomics and pathology. He is a board-certified pathologist with expertise in prostate cancer pathology and the translation of novel findings to clinical investigations. As a laboratory-based researcher, He has more than 15 years experience in biomarker discovery and characterization. He is currently Co-PI with Dr. Arul M. Chinnaiyan (University of Michigan) of a Biomarker Discovery Laboratory of the EDRN, and works closely with Dr. Levi Garraway (Broad Institute) on whole genome and exome sequencing of prostate cancer. In his role as a scientific leader at Weill Cornell Medicine,
He is the Founding Director of the recently established Englander Institute for Precision Medicine.
His primary responsibility is for its scientific development and oversight for all genomics, computational cancer genomics, and biobanking activities related to the diagnosis and treatment of cancers. Among his seminal observations in prostate cancer genomics and biomarker development, he was the co-Senior Investigator of the first gene expression profiling study in prostate cancer (Nature, 2001) and the first whole genome and exome DNA sequencing studies in prostate cancer (Nature, 2011 and Nature Genetics, 2012). This work led to the discovery and development of several prostate cancer biomarkers, including AMACR, Hepsin, Pim1, EZH2, JAGGED1, SPOP, MED12, MYCN, and AURKA. Working with Dr. Chinnaiyan, he played a pivotal role in the landmark discovery of recurrent ETS rearrangements in prostate cancer, most often involving TMPRSS2:ERG (Science, 2005). His recent genomics work has defined an SPOP mutant subclass of prostate cancer, as defined by a high susceptibility to double stranded DNA damage (Cell, 2013). Additionally, his discovery of AURKA/MYCN amplified aggressive prostate cancer (Cancer Discovery, 2013) has led to a Phase II Trial of MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine PCa (NCT01799278).